? SMALL ANIMAL IMAGING SHARED RESOURCE (SAISR) The SAISR provides critical support to OSUCCC?s preclinical imaging needs and translational therapeutic development to provide a fundamental service for monitoring live animal tumor progression and regression, metastatic spread, and response to therapeutic interventions. Services include pre-study consultation, small animal imaging, analysis and data interpretation, and education and training. Major equipment in SAISR includes a Bruker 9.4T MRI, a Vevo high frequency ultrasound, an IVIS Lumina II, a Bruker Skyscan 1276 microCT, an Xstrahl Small Animal Radiation Research Platform, and an Echo-MRI. SAISR?s Specific Aims are to: 1) provide OSUCCC investigators? access to high resolution non-invasive small animal imaging technologies that can be used to evaluate small animal cancer models and treatment therapies in vivo; 2) provide accurate qualitative image interpretation and quantitative image data analysis to al OSUCCC users; 3) identify, evaluate, and implement new and emerging technologies that address specific needs of the OSUCCC investigators; and 4) recognize and promote integration of other shared resource services that add value to investigators studies, such as the CPDISR that provides necropsy and pathology services for mice, and the MSR that provides high resolution microscopy imaging of ex vivo tissue samples. The SAISR is located within the Biomedical Research Tower, centrally located to most OSUCCC researchers. The Director of the SAISR is Dr. Kimberly Powell, who has managed the facility since 2011. The Senior Faculty Advisor is Dr. Nicholas Denko (CB), who provides overall scientific vision for the SAISR. During current grant cycle, the SAISR identified important new imaging modalities (echoMRI, the Xtrahl SAARP, and the SkyScan 1276 microCT) and worked with investigators and the OSUCCC to obtain them. During this time period, the SAISR has contributed to 41 publications (9 > 10 impact factor), 156 users, and 41 NCI including 27 R01s, 3 R21s, 4 U01s, 5 P01s, 1 P50 and 1 R03, involving members from all five programs. Given the robust OSUCCC recruitment of the OSUCCC and its research priorities, demand for services and new technologies will increase. The SAISR will expand its staff, instrumentation and services before capacity is reached. Additionally, the SAISR will add PET scanning and optoacoustic imaging. SAISR is working to: 1) develop optimized protocols for quantifying lung metastases and pancreatic tumor burden using the newly acquired microCT; 2) collaborate with the CPDISR, MSR, and TVdSR and the Genetically Engineered Mouse Models Core (a non-CCSG activity) to comprehensively characterize disease progression in mouse cancer models (i.e., lung, pancreatic, glioblastoma, and breast); and 3) expand molecular imaging capabilities. If images are digitized, they could be used for machine learning techniques. The SAISR will be a regular member of the Immune Monitoring and Discovery Platform. The annual budget is $575,505, yet the CCSG request is $61,080. Thus, the SAISR leverages extensive institutional support and seeks only 10.6% support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications